Phoenix Lab, an AI drug discovery startup co-founded by SK Networks and Stanford University talent, has secured $8 million in seed funding. The round was led by Menlo Ventures, with notable investors including former Apple SVP of Machine Learning and AI John Giannandrea.
TL;DR
- Phoenix Lab raises $8M in seed funding to accelerate global expansion.
- Menlo Ventures leads the round, with investments from high-profile industry figures.
- The funding will enhance the company's RAG-based AI drug discovery platform, Cheiron.
What happened
Phoenix Lab, an AI drug discovery startup, has raised $8 million in seed funding. The round was led by Menlo Ventures, a prominent Silicon Valley venture capital firm known for its investments in companies like Anthropic and Uber. Other investors include former Starbucks CEO Laxman Narasimhan and ex-Apple SVP of Machine Learning and AI John Giannandrea.
The funding will be used to enhance the company's RAG-based AI drug discovery solution, Cheiron, and to recruit top talent. Cheiron leverages a proprietary Life Sciences Knowledge Graph to support decision-making throughout the drug development process. The platform is currently used by major South Korean pharmaceutical and biotech companies for clinical development, regulatory affairs, and competitive intelligence analysis.
This marks the first external investment secured by a company born from SK Networks' in-house startup incubation program. Phoenix Lab was established in 2024 through SK Networks' early-stage corporate incubation program, with CEO Bae Min-seok and other Stanford researchers recruited by SK Networks' President of Business Operations, Choi Sung-hwan.
Why it matters
The investment highlights the growing interest in AI-driven drug discovery and the potential of Phoenix Lab's technology to transform the drug development process. The involvement of high-profile investors like Menlo Ventures and John Giannandrea adds credibility to the startup's vision and technology.
For developers and startups in the AI and biotech space, this funding round underscores the importance of leveraging advanced AI techniques like RAG and knowledge graphs to solve complex problems in drug discovery. It also highlights the potential for collaboration between academia, industry, and venture capital to drive innovation in the life sciences sector.
Investors should take note of the growing trend of AI applications in the biotech industry, as well as the increasing involvement of high-profile individuals in early-stage investments. The success of Phoenix Lab's funding round could pave the way for more investments in AI-driven drug discovery startups, particularly those with strong technical foundations and strategic partnerships.
Key facts
- Phoenix Lab raises $8 million in seed funding.
- Menlo Ventures leads the seed round.
- Investors include former Apple SVP of Machine Learning and AI John Giannandrea and former Starbucks CEO Laxman Narasimhan.
- The company's RAG-based AI drug discovery solution is called Cheiron.
- Cheiron leverages a proprietary Life Sciences Knowledge Graph to support drug development decision-making.
- The funding will be used to enhance the Cheiron platform and recruit top talent.
- Phoenix Lab was established in 2024 through SK Networks' early-stage corporate incubation program.
- Major South Korean pharmaceutical and biotech companies are already using the Cheiron platform.
Context
The AI drug discovery market is gaining traction as companies seek to leverage advanced technologies to streamline the drug development process. AI-driven solutions like Cheiron have the potential to significantly reduce the time and cost associated with bringing new drugs to market, making them an attractive investment for venture capital firms and industry experts.
The involvement of high-profile investors like John Giannandrea and Laxman Narasimhan highlights the growing interest in AI applications within the biotech industry. These investors bring valuable expertise and networks that can help startups like Phoenix Lab scale and succeed in the competitive global market.
As the AI and biotech sectors continue to converge, we can expect to see more collaborations between academic institutions, industry leaders, and venture capital firms. These partnerships will be crucial in driving innovation and addressing the complex challenges facing the life sciences sector.
